Abstract
Second-generation antipsychotic medications are recommended as first-line treatments for people experiencing psychosis, but many of these drugs are closely associated with metabolic changes that significantly contribute towards poor physical health and increased mortality rates. Current evidence suggests that considerable variations exist among this group of drugs with respect to their independent effects on metabolism—some of these discrepancies probably relate to their differing effects on neurotransmitters. This article explores some of the more commonly accepted hypotheses for the reasons antipsychotics contribute towards metabolic disorders and discusses the potential implications for practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
